TAP Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Lake Forest IL United States (1977)
Status: Acquired by Takeda (2008)

Organization Overview

First Clinical Trial
2001
NCT00220350
First Marketed Drug
1987
cefmenoxime (cefmax)
First NDA Approval
1987
cefmenoxime (cefmax)
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Schober, Justine, M.D. | TAP PHARM | TAP Pharmaceutical Products Inc.

Active Ingredients

Marketed Drugs (3)

cefditoren (spectracef) (2001 NDA)

cefmenoxime (cefmax) (1987 NDA)

leuprolide (lupron) (NDA)

Drugs in Phase 4 Trials (2)

lansoprazole (prevacid) (6 trials)

somatropin (protropin) (1 trial)

Drugs in Phase 3 Trials (3)

leuprolide (lupron) (3 trials)

levobupivacaine (chirocaine) (1 trial)

triamcinolone (kenalog) (1 trial)

Drugs in Phase 2 Trials (3)

asoprisnil (1 trial)

hemopoietic stem cell (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Other Trials (1)

dexlansoprazole (dexilant) (1 trial)

Indications

Approved Indications


 

Bronchitis, Chronic

Endometriosis

Leiomyoma

Otitis Externa

Otitis Media

Pharyngitis

Pneumonia, Bacterial

Prostatic Neoplasms

Sinusitis

Skin Diseases, Bacterial

Tonsillitis

Urinary Tract Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amenorrhea (Phase 2)

Dysphonia (Phase 4)

Eosinophilic Esophagitis (Phase 4)

Esophagitis (Phase 4)

Gastroesophageal Reflux (Phase 4)

Heartburn (Phase 4)

Hoarseness (Phase 4)

Hypothyroidism (Phase 4)

Insulin Resistance (Phase 2)

Laryngeal Diseases (Phase 3)

Menopause, Premature (Phase 2)

Menorrhagia (Phase 2)

Pancreatitis (Phase 3)

Pancreatitis, Chronic (Phase 3)

Pedophilia (Phase 3)

Primary Ovarian Insufficiency (Phase 2)

Stomach Ulcer (Phase 4)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 9